Study S003380

A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Co-administration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight With Co-morbidity (ASCEND)

ClinicalTrials.gov record

Registration

Registration: NCT06862791
Acronym: ASCEND
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 377
Start: 2025-02-18
Primary completion: 2026-05-11
Lead sponsor: AstraZeneca
Conditions: Obesity or Overweight
Interventions: DRUG:AZD9550; DRUG:AZD6234; DRUG:Placebo comparator
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: REGISTRY:2024-516176-15-00

Registered primary outcomes

Percent change in body weight from baseline after 36 weeks of treatment [36 weeks]
Weight loss ≥ 5% from baseline after 36 weeks of treatment [36 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.